DEFA14A: Paratek Pharmaceuticals to Acquire Optinose for Up to $330 Million, Expanding Commercial Reach for XHANCE

Paratek Pharmaceuticals will acquire Optinose in a deal valued at up to $330 million, aiming to leverage Paratek's commercial infrastructure to broaden the reach of Optinose's XHANCE for chronic rhinosinusitis.

Summary

• Paratek Pharmaceuticals is set to acquire Optinose, including its product XHANCE, for a total transaction value of up to $330 million.
• The deal includes an upfront consideration of $9 per share in cash and a contingent value right (CVR) of up to $5 per share, tied to future commercial milestones.
• The acquisition aims to expand Paratek's commercial portfolio beyond its antibiotic NUZYRA and strengthen its position as a multi-product company.
• XHANCE is approved for chronic rhinosinusitis (CRS) with or without nasal polyps, and the acquisition will leverage Paratek's primary care field force to accelerate its adoption.
• The transaction is financed by capital from Paratek, B-FLEXION Life Sciences, and Novo Holdings, along with debt financing from Oaktree Capital Management, L.P.
• The deal is expected to close as early as mid-2025, subject to customary closing conditions, including Optinose shareholder approval and regulatory clearances.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the acquisition premium, potential for XHANCE growth, and expansion of Paratek's portfolio. However, risks related to regulatory approvals and sales milestones temper the overall sentiment.

Positives

• The acquisition expands Paratek's commercial portfolio beyond its flagship antibiotic, NUZYRA.
• Paratek will leverage its expanded commercial infrastructure to accelerate awareness and adoption of XHANCE among both ENT and allergy specialists and primary care providers.
• The upfront consideration of $9 per share represents a 50% premium to Optinose's closing trading price on March 19, 2025.
• The deal provides Optinose shareholders with potential additional value through contingent value rights (CVRs) tied to XHANCE sales milestones.

Negatives

• The deal is subject to customary closing conditions, including Optinose shareholder approval and regulatory clearances, which could delay or prevent the transaction from closing.
• The CVRs are contingent on XHANCE achieving specific net sales milestones, which may not be met.
• Optinose's common stock will be delisted from the NASDAQ Global Market upon completion of the acquisition.

Risks

• The proposed transaction may not be completed in a timely manner or at all, which may adversely affect Optinose's business and stock price.
• Failure to obtain necessary regulatory approvals or Optinose stockholder approval could prevent the merger.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement.
• Risks relating to the achievement of the milestones necessary for the payment of any contingent value rights.
• Disruption from the pending Merger making it more difficult to maintain business and operational relationships.
• Negative effects of the announcement of the Merger or the consummation of the Merger on the market price of Optinose's common stock and on Optinose's operating results.
• The impact of competitive products and pricing on XHANCE sales.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.

Future Outlook

The acquisition is expected to close as early as mid-2025, subject to customary closing conditions. Paratek aims to leverage its commercial infrastructure to expand the reach of XHANCE and create a stronger platform for future product acquisitions.

Management Comments

• Evan Loh, MD, Chief Executive Officer of Paratek, stated that the transaction creates a stronger platform for future product acquisitions.
• Ramy Mahmoud, MD, MPH, Chief Executive Officer of Optinose, expressed excitement about the potential for Paratek to rapidly extend awareness of XHANCE to primary care providers.

Industry Context

This acquisition reflects a trend in the pharmaceutical industry towards consolidation and portfolio expansion. Paratek's acquisition of Optinose allows it to diversify its product offerings and leverage its existing commercial infrastructure to reach a broader patient base. The focus on innovative specialty therapies for primary care providers and specialists aligns with the industry's shift towards addressing unmet medical needs in targeted patient populations.

Comparison to Industry Standards

• The acquisition of Optinose by Paratek is similar to other pharmaceutical company acquisitions focused on expanding product portfolios and leveraging commercial synergies.
• For example, acquisitions of smaller biotech companies with promising drugs by larger pharmaceutical firms are common in the industry.
• The contingent value rights (CVRs) structure is also a relatively common mechanism used in pharmaceutical acquisitions to align the interests of the acquiring and acquired companies and to share the risks and rewards of future product performance.
• Comparable companies that have used CVRs in acquisitions include Sanofi's acquisition of Genzyme and Bristol-Myers Squibb's acquisition of Celgene.

Stakeholder Impact

• Optinose's shareholders will receive a premium for their shares and potential additional value through CVRs.
• Paratek's shareholders will benefit from the expanded product portfolio and potential revenue synergies.
• Patients with chronic rhinosinusitis may benefit from increased awareness and access to XHANCE.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the integration.

Next Steps

• Optinose will file documents with the SEC, including preliminary and definitive proxy statements.
• Optinose's stockholders will vote on the proposed transaction.
• The transaction is subject to customary closing conditions, including regulatory clearances.
• Paratek will integrate Optinose's operations and commercialize XHANCE.

Key Dates

Keywords

Optinose, Paratek Pharmaceuticals, XHANCE, Merger, Acquisition, Chronic Rhinosinusitis, NUZYRA, Contingent Value Rights, Pharmaceuticals